France · Delayed Price · Currency is EUR Transgene Earnings Call Transcripts
Fiscal Year 2026
-
Significant advances were presented in individualized neoantigen vaccines, with TG4050 progressing in head and neck cancer and TG4070 launching in non-small cell lung cancer. Manufacturing is transitioning to a scalable cell line process, and the SNIPER platform is validated for future indications. Expansion into Monkeypox/Smallpox vaccines leverages these innovations.
Fiscal Year 2025
-
Strong clinical progress in 2025 with TG4050 showing 100% disease-free survival in phase I, robust fundraising securing operations through early 2028, and preparations for new trials and manufacturing scale-up. Key data readouts and industry partnerships are anticipated in the coming years.
-
TG4050 demonstrated 100% disease-free survival at 24 months in phase I for operable head and neck cancer, with robust, durable T cell responses and strong translational support for its mechanism. Phase II and new combination trials are progressing, with key data expected from 2026 onward.
-
TG4050 achieved 100% disease-free survival at 24 months in phase I for operable head and neck cancer, with phase II progressing and key data expected through 2027. Financials are stable, with funding secured to end-2026 and a strategic focus on the myvac platform.
-
TG4050, an individualized neoantigen cancer vaccine, showed 100% relapse-free survival at 30 months in phase I for high-risk head and neck cancer, with robust and durable immune responses. Phase II is underway, and late-stage development and new indications are planned, supported by manufacturing scale-up.
Fiscal Year 2024
-
Clinical proof of concept for TG4050 was achieved, with all treated patients disease-free at 24 months. Financials are on track, with funding secured through April 2026. Key data readouts for TG4050, TG4001, BT-001, and TG6050 are expected throughout 2025.
-
A phase 2 trial of TG4001 plus avelumab in advanced HPV-16-positive cancers did not meet its primary endpoint, but a trend toward efficacy was observed in cervical cancer patients. Full results and further analyses will be presented in 2025.
-
Significant clinical progress was made in immunotherapy programs, with TG4050 and TG4001 advancing in trials and strong early results reported. Financial stability is ensured through Q4 2025 after a major debt-to-equity conversion, and no R&D budget increase is planned.